CN117241838A - 经修饰的多肽和其用途 - Google Patents

经修饰的多肽和其用途 Download PDF

Info

Publication number
CN117241838A
CN117241838A CN202280030397.1A CN202280030397A CN117241838A CN 117241838 A CN117241838 A CN 117241838A CN 202280030397 A CN202280030397 A CN 202280030397A CN 117241838 A CN117241838 A CN 117241838A
Authority
CN
China
Prior art keywords
cyclin
polypeptide
seq
nucleic acid
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280030397.1A
Other languages
English (en)
Chinese (zh)
Inventor
罗杰·钟
艾伯特·李
斯蒂芬妮·瑞纳
马尔科·莫尔施
卢安·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macquarie University
Original Assignee
Macquarie University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021901193A external-priority patent/AU2021901193A0/en
Application filed by Macquarie University filed Critical Macquarie University
Publication of CN117241838A publication Critical patent/CN117241838A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/095—Fusion polypeptide containing a localisation/targetting motif containing a nuclear export signal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280030397.1A 2021-04-22 2022-04-22 经修饰的多肽和其用途 Pending CN117241838A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021901193 2021-04-22
AU2021901193A AU2021901193A0 (en) 2021-04-22 Modified polypeptides and uses thereof
PCT/AU2022/050366 WO2022221922A1 (en) 2021-04-22 2022-04-22 Modified polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
CN117241838A true CN117241838A (zh) 2023-12-15

Family

ID=83723498

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280030397.1A Pending CN117241838A (zh) 2021-04-22 2022-04-22 经修饰的多肽和其用途

Country Status (7)

Country Link
US (1) US20240199713A1 (https=)
EP (1) EP4326340A4 (https=)
JP (1) JP2024515307A (https=)
CN (1) CN117241838A (https=)
AU (1) AU2022261654A1 (https=)
CA (1) CA3215808A1 (https=)
WO (1) WO2022221922A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025007194A1 (en) * 2023-07-05 2025-01-09 Macquarie University Modulation of gene expression
WO2025081231A1 (en) * 2023-10-16 2025-04-24 Infensa Bioscience Pty Ltd Inhibitors and uses therefor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3535403A4 (en) * 2016-11-07 2020-08-12 MacQuarie University MODULATION OF PROTEIN ACCUMULATION AND ASSOCIATED USES
CA3126918A1 (en) * 2019-01-14 2020-07-23 President And Fellows Of Harvard College Methods and compositions for restoring stmn2 levels

Also Published As

Publication number Publication date
JP2024515307A (ja) 2024-04-08
US20240199713A1 (en) 2024-06-20
AU2022261654A1 (en) 2023-11-09
AU2022261654A9 (en) 2023-11-16
WO2022221922A1 (en) 2022-10-27
CA3215808A1 (en) 2022-10-27
EP4326340A4 (en) 2025-04-16
EP4326340A1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
JP7221275B2 (ja) Ａａｖを送達するための組成物および方法
US20220333131A1 (en) Modulatory polynucleotides
US10301366B2 (en) Compositions and methods for treatment of disorders related to CEP290
AU2018352236B2 (en) Treatment of amyotrophic lateral sclerosis (ALS)
AU2018375192B2 (en) Engineered DNA binding proteins
AU2008216018B2 (en) Mitochondrial nucleic acid delivery systems
EP2844302A2 (en) Viral vectors for the treatment of retinal dystrophy
US20220168450A1 (en) Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
CN113710693B (zh) Dna结合结构域反式激活因子及其用途
KR20170098931A (ko) 뇌 질환을 치료하기 위한 방법 및 조성물
US20240424039A1 (en) Aav-mediated gene transfer for retinopathy
US20220362404A1 (en) Modulation of cellular viability
CN117241838A (zh) 经修饰的多肽和其用途
JP2021535168A (ja) 筋萎縮性側索硬化症の治療方法または予防方法
US20240115736A1 (en) Methods and materials for treating tdp-43 proteinopathies
JP2025523953A (ja) 肢帯型筋ジストロフィーのためのａｕｆ１遺伝子療法
WO2025007194A1 (en) Modulation of gene expression

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination